Effectiveness of SGLT2 inhibitors in slowing chronic kidney disease progression and reducing mortality: a meta-analysis

BackgroundChronic kidney disease (CKD) represents a significant health problem worldwide with high morbidity, mortality, and development of end-stage kidney disease (ESKD). Sodium-glucose co-transporter 2 (SGLT2) inhibitors represent an innovative class of medications with possible cardiorenal advan...

Descripció completa

Dades bibliogràfiques

Autors principals:	Arjun Sharma, Bharat Sharma, Deepthi Sree Vamaraju, Amrendra Kumar Ajay
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2026-08-01
Col·lecció:	Frontiers in Pharmacology
Matèries:	chronic kidney disease (CKD) end-stage kidney disease (ESKD) estimated glomerular filtration rate (eGFR) renal progression SGLT2 inhibitors
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fphar.2026.1923548/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!